.jpg.aspx "TechDogs-\"Epinephrine autoinjector market to grow at 8.07% Y-O-Y in 2023; Increasing prevalence of allergies will drive growth -Technavio\"")
Market Research
Epinephrine autoinjector market to grow at 8.07% Y-O-Y in 2023; Increasing prevalence of allergies will drive growth -Technavio
By PR Newswire
Share
NEW YORK, Dec. 19, 2022 /PRNewswire/ --
Epinephrine autoinjector market insights -
- Vendors: 15+, including Adamis Pharmaceuticals Corp., ALK Abello AS, Amneal Pharmaceuticals Inc., BIOPROJET, Crossject, Halozyme Therapeutics Inc., kaleo Inc., Shionogi and Co. Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Windgap Medical Inc., Bausch Health Co Inc., among others
- Coverage: Parent market analysis; key drivers, major trends, and challenges; customer and vendor landscape; vendor product insights and recent developments; key vendors; and market positioning of vendors
- Segments: Dosage, End-user, and Geography
To understand more about the epinephrine autoinjector market, request a sample report
In 2017, the epinephrine autoinjector market was valued at USD 2,641.44 million. From a regional perspective, North America held the largest market share, valued at USD 1,239.71 million. The epinephrine autoinjector market size is estimated to grow by USD 2,014.33 million from 2022 to 2027 at a CAGR of 9.68% according to Technavio.
Why Buy?
- Add credibility to strategy
- Analyzes competitor's offerings
- Get a holistic view of the market
Grow your profit margin with Technavio- Buy the Report
Epinephrine autoinjector market - Customer Landscape
To help companies evaluate and develop growth strategies, the report outlines –
- Key purchase criteria
- Adoption rates
- Adoption lifecycle
- Drivers of price sensitivity
- For highlights on customer landscape analysis, download a sample!
Epinephrine autoinjector market - Vendor Insights
The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Technavio report analyzes the market's competitive landscape and offers information on several market vendors including –
- Adamis Pharmaceuticals Corp. - The company offers epinephrine autoinjectors such as SYMJEPI 0.15mg and SYMJEPI 0.3mg.
- Amneal Pharmaceuticals Inc. - The company offers epinephrine autoinjectors such as Adrenaclick 0.15 mg and Adrenaclick 0.3 mg.
- BIOPROJET - The company offers epinephrine autoinjectors such as Emerade 500mcg, 300mcg, and 150mcg.
- Crossject - The company offers epinephrine autoinjector namely, Anapen.
Epinephrine autoinjector market – Market Dynamics
Major Drivers –
- Increasing prevalence of allergies
- Marketing strategies
- Rise in awareness of anaphylaxis and availability of innovative epinephrine autoinjectors
KEY challenges –
- Product recalls and regulatory issues
- Presence of substitutes
- High cost of epinephrine autoinjector
The epinephrine autoinjector market report provides critical information and factual data, with a qualitative and quantitative study of the market based on market drivers and limitations as well as future prospects.
What are the key data covered in this epinephrine autoinjector market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the epinephrine autoinjector market between 2023 and 2027
- Precise estimation of the size of the epinephrine autoinjector market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the epinephrine autoinjector market industry across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market's competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of epinephrine autoinjector market vendors
Gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
Related Reports:
- The medical imaging market is estimated to grow at a CAGR of 5.7% between 2022 and 2027. The size of the market is forecast to increase by USD 12.87 billion. The increasing prevalence of chronic conditions is notably driving the medical imaging market growth, although factors such as high costs associated with medical imaging may impede the market growth.
- The endoscopic closure devices market is estimated to grow at a CAGR of 7.16% between 2022 and 2027. The size of the market is forecast to increase by USD 633.13 million. The increasing volume of endoscopy procedures coupled with the growing target population is notably driving the market growth, although factors such as the high cost of endoscopy procedures may impede the market growth.
|
Epinephrine Autoinjector Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
151 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 9.68% |
|
Market growth 2023-2027 |
USD 2014.33 million |
|
Market structure |
Concentrated |
|
YoY growth 2022-2023 (%) |
8.07 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 46% |
|
Key countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Adamis Pharmaceuticals Corp., ALK Abello AS, Amneal Pharmaceuticals Inc., BIOPROJET, Crossject, Halozyme Therapeutics Inc., kaleo Inc., Shionogi and Co. Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Windgap Medical Inc., and Bausch Health Co Inc. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of contents:
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Dosage
- Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global epinephrine autoinjector market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global epinephrine autoinjector market 2017 - 2021 ($ million)
- 4.2 Dosage Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Dosage Segment 2017 - 2021 ($ million)
- 4.3 End-user Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – End-user Segment 2017 - 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
- 4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Dosage
- 6.1 Market segments
- Exhibit 30: Chart on Dosage - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Dosage - Market share 2022-2027 (%)
- 6.2 Comparison by Dosage
- Exhibit 32: Chart on Comparison by Dosage
- Exhibit 33: Data Table on Comparison by Dosage
- 6.3 0.30gm - Market size and forecast 2022-2027
- Exhibit 34: Chart on 0.30gm - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on 0.30gm - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on 0.30gm - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on 0.30gm - Year-over-year growth 2022-2027 (%)
- 6.4 0.15gm - Market size and forecast 2022-2027
- Exhibit 38: Chart on 0.15gm - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on 0.15gm - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on 0.15gm - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on 0.15gm - Year-over-year growth 2022-2027 (%)
- 6.5 0.50gm - Market size and forecast 2022-2027
- Exhibit 42: Chart on 0.50gm - Market size and forecast 2022-2027 ($ million)
- Exhibit 43: Data Table on 0.50gm - Market size and forecast 2022-2027 ($ million)
- Exhibit 44: Chart on 0.50gm - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on 0.50gm - Year-over-year growth 2022-2027 (%)
- 6.6 Market opportunity by Dosage
- Exhibit 46: Market opportunity by Dosage ($ million)
7 Market Segmentation by End-user
- 7.1 Market segments
- Exhibit 47: Chart on End-user - Market share 2022-2027 (%)
- Exhibit 48: Data Table on End-user - Market share 2022-2027 (%)
- 7.2 Comparison by End-user
- Exhibit 49: Chart on Comparison by End-user
- Exhibit 50: Data Table on Comparison by End-user
- 7.3 Hospitals and clinics - Market size and forecast 2022-2027
- Exhibit 51: Chart on Hospitals and clinics - Market size and forecast 2022-2027 ($ million)
- Exhibit 52: Data Table on Hospitals and clinics - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Chart on Hospitals and clinics - Year-over-year growth 2022-2027 (%)
- Exhibit 54: Data Table on Hospitals and clinics - Year-over-year growth 2022-2027 (%)
- 7.4 Homecare - Market size and forecast 2022-2027
- Exhibit 55: Chart on Homecare - Market size and forecast 2022-2027 ($ million)
- Exhibit 56: Data Table on Homecare - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Chart on Homecare - Year-over-year growth 2022-2027 (%)
- Exhibit 58: Data Table on Homecare - Year-over-year growth 2022-2027 (%)
- 7.5 Market opportunity by End-user
- Exhibit 59: Market opportunity by End-user ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 61: Chart on Market share by geography 2022-2027 (%)
- Exhibit 62: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 63: Chart on Geographic comparison
- Exhibit 64: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2022-2027
- Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)
- 9.4 Europe - Market size and forecast 2022-2027
- Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
- 9.5 Asia - Market size and forecast 2022-2027
- Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- 9.7 US - Market size and forecast 2022-2027
- Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)
- 9.8 Germany - Market size and forecast 2022-2027
- Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
- 9.9 UK - Market size and forecast 2022-2027
- Exhibit 89: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 90: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 91: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 92: Data Table on UK - Year-over-year growth 2022-2027 (%)
- 9.10 China - Market size and forecast 2022-2027
- Exhibit 93: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 94: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 95: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 96: Data Table on China - Year-over-year growth 2022-2027 (%)
- 9.11 Japan - Market size and forecast 2022-2027
- Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%)
- Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 101: Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 102: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 104: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 105: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 106: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 107: Matrix on vendor position and classification
- 12.3 Adamis Pharmaceuticals Corp.
- Exhibit 108: Adamis Pharmaceuticals Corp. - Overview
- Exhibit 109: Adamis Pharmaceuticals Corp. - Business segments
- Exhibit 110: Adamis Pharmaceuticals Corp. - Key offerings
- Exhibit 111: Adamis Pharmaceuticals Corp. - Segment focus
- 12.4 ALK Abello AS
- Exhibit 112: ALK Abello AS - Overview
- Exhibit 113: ALK Abello AS - Product / Service
- Exhibit 114: ALK Abello AS - Key offerings
- 12.5 Amneal Pharmaceuticals Inc.
- Exhibit 115: Amneal Pharmaceuticals Inc. - Overview
- Exhibit 116: Amneal Pharmaceuticals Inc. - Business segments
- Exhibit 117: Amneal Pharmaceuticals Inc. - Key news
- Exhibit 118: Amneal Pharmaceuticals Inc. - Key offerings
- Exhibit 119: Amneal Pharmaceuticals Inc. - Segment focus
- 12.6 Bausch Health Co Inc.
- Exhibit 120: Bausch Health Co Inc. - Overview
- Exhibit 121: Bausch Health Co Inc. - Business segments
- Exhibit 122: Bausch Health Co Inc. - Key news
- Exhibit 123: Bausch Health Co Inc. - Key offerings
- Exhibit 124: Bausch Health Co Inc. - Segment focus
- 12.7 BIOPROJET
- Exhibit 125: BIOPROJET - Overview
- Exhibit 126: BIOPROJET - Product / Service
- Exhibit 127: BIOPROJET - Key offerings
- 12.8 Crossject
- Exhibit 128: Crossject - Overview
- Exhibit 129: Crossject - Product / Service
- Exhibit 130: Crossject - Key offerings
- 12.9 Halozyme Therapeutics Inc.
- Exhibit 131: Halozyme Therapeutics Inc. - Overview
- Exhibit 132: Halozyme Therapeutics Inc. - Product / Service
- Exhibit 133: Halozyme Therapeutics Inc. - Key offerings
- 12.10 kaleo Inc.
- Exhibit 134: kaleo Inc. - Overview
- Exhibit 135: kaleo Inc. - Product / Service
- Exhibit 136: kaleo Inc. - Key offerings
- 12.11 Shionogi and Co. Ltd.
- Exhibit 137: Shionogi and Co. Ltd. - Overview
- Exhibit 138: Shionogi and Co. Ltd. - Product / Service
- Exhibit 139: Shionogi and Co. Ltd. - Key offerings
- 12.12 Teva Pharmaceutical Industries Ltd.
- Exhibit 140: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 141: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 142: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 143: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 144: Teva Pharmaceutical Industries Ltd. - Segment focus
- 12.13 Viatris Inc.
- Exhibit 145: Viatris Inc. - Overview
- Exhibit 146: Viatris Inc. - Business segments
- Exhibit 147: Viatris Inc. - Key offerings
- Exhibit 148: Viatris Inc. - Segment focus
- 12.14 Windgap Medical Inc.
- Exhibit 149: Windgap Medical Inc. - Overview
- Exhibit 150: Windgap Medical Inc. - Product / Service
- Exhibit 151: Windgap Medical Inc. - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 152: Inclusions checklist
- Exhibit 153: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 154: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 155: Research methodology
- Exhibit 156: Validation techniques employed for market sizing
- Exhibit 157: Information sources
- 13.5 List of abbreviations
- Exhibit 158: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/epinephrine-autoinjector-market-to-grow-at-8-07-y-o-y-in-2023-increasing-prevalence-of-allergies-will-drive-growth--technavio-301705180.html
SOURCE Technavio
Like what you read? Head to the TechDogs homepage to find the latest tech content infused with drama and entertainment. We've got Articles, White Papers, Case Studies, Reports, Videos and Events - the complete lot to help you Know Your World of Technology.
First published on Mon, Dec 19, 2022
Enjoyed what you read? Great news – there’s a lot more to explore!
Dive into our content repository of the latest tech news, a diverse range of articles spanning introductory guides, product reviews, trends and more, along with engaging interviews, up-to-date AI blogs and hilarious tech memes!
Also explore our collection of branded insights via informative white papers, enlightening case studies, in-depth reports, educational videos and exciting events and webinars from leading global brands.
Head to the TechDogs homepage to Know Your World of technology today!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. All information / content found on TechDogs' site may not necessarily be reviewed by individuals with the expertise to validate its completeness, accuracy and reliability.
Tags:
- Promoted By TechDogs -
Related Content on Market Research
Join The Discussion